<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00161447</url>
  </required_header>
  <id_info>
    <org_study_id>04-0832-D</org_study_id>
    <secondary_id>U54HD042454</secondary_id>
    <nct_id>NCT00161447</nct_id>
  </id_info>
  <brief_title>Male Hormonal Contraceptive Development-ACY-5</brief_title>
  <acronym>ACY-5</acronym>
  <official_title>Male Hormonal Contraceptive Development: Suppression of Spermatogenesis With the Addition of a Potent Antagonist (Acyline) to Testosterone and DMPA (ACY-5)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>CONRAD</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to help in the development of male contraception (birth
      control).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective is to conduct a male contraceptive trial in which we will evaluate the
      suppressive effects of acyline when administered in combination with Testosterone (T) and the
      progestin depo-medroxyprogesterone acetate (DMPA).

      We will be administering combinations of three drugs: Testosterone (T) by gel, Depot
      Medroxyprogesterone acetate (DMPA) and Acyline to see their effects on sperm production. The
      T/DMPA/Acyline combination will allow us to determine if the more rapid and complete
      gonadotropin suppression mediated by the early addition of a GnRH antagonist will accelerate
      and enhance suppression of spermatogenesis.

      In prior studies with testosterone and DMPA these drug, which are hormones, have been found
      to be safe, and to reversibly suppress sperm counts to zero in about 80% of men. We hope to
      improve this to 100% of men by adding another drug, Acyline.

      Acyline is an GnRH antagonist which blocks the release of LH and FSH from the pituitary. DMPA
      is approved by the FDA for use as a female contraceptive. The endpoint will be suppression of
      spermatogenesis to zero (azoospermia) by the end of the treatment phase.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">April 2006</completion_date>
  <primary_completion_date type="Actual">April 2006</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary biological end points in this trial will be suppression of spermatogenesis and gonadotropins while monitoring for any adverse changes in lipid metabolism, sexual side effects or in general health</measure>
    <time_frame>One year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Regimen acceptability, sexual function, glucose tolerance, intratesticular hormone levels</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Testosterone (T) gel for 6 months + DMPA (injected into muscle once)on Day 0 and at Month 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Testosterone (T) gel for 6 months + DMPA (injected into muscle on Day 0 &amp; at month 3) + Acyline (SQ) every two weeks for the first 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acyline</intervention_name>
    <description>Acyline 300 mcg/kg SQ every 2 weeks for 12 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone Gel</intervention_name>
    <description>Testosterone Gel (10 g daily</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Testim</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Depo-Medroxyprogesterone</intervention_name>
    <description>DMPA (injected into muscle) Day 0 &amp; month 3</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>DMPA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males between 18-55

          -  In good general health

          -  With normal sperm counts

          -  Willing to use an acceptable form of contraception

        Exclusion Criteria:

          -  Men in poor health

          -  Significant chronic or acute medical illness

          -  Skin conditions that might interfere with or be exacerbated by testosterone gel

          -  Known history of alcohol, illicit drug or anabolic steroid abuse

          -  Abnormal reproductive function

          -  Participation in a long-term male contraceptive study within past three months
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William J Bremner, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://depts.washington.edu/popctr/</url>
    <description>http://depts.washington.edu/popctr</description>
  </link>
  <reference>
    <citation>Meriggiola MC, Bremner WJ, Costantino A, Di Cintio G, Flamigni C. Low dose of cyproterone acetate and testosterone enanthate for contraception in men. Hum Reprod. 1998 May;13(5):1225-9.</citation>
    <PMID>9647551</PMID>
  </reference>
  <reference>
    <citation>Anawalt BD, Bebb RA, Bremner WJ, Matsumoto AM. A lower dosage levonorgestrel and testosterone combination effectively suppresses spermatogenesis and circulating gonadotropin levels with fewer metabolic effects than higher dosage combinations. J Androl. 1999 May-Jun;20(3):407-14.</citation>
    <PMID>10386821</PMID>
  </reference>
  <reference>
    <citation>Kamischke A, Venherm S, Pl√∂ger D, von Eckardstein S, Nieschlag E. Intramuscular testosterone undecanoate and norethisterone enanthate in a clinical trial for male contraception. J Clin Endocrinol Metab. 2001 Jan;86(1):303-9.</citation>
    <PMID>11232016</PMID>
  </reference>
  <reference>
    <citation>Herbst KL, Anawalt BD, Amory JK, Bremner WJ. Acyline: the first study in humans of a potent, new gonadotropin-releasing hormone antagonist. J Clin Endocrinol Metab. 2002 Jul;87(7):3215-20.</citation>
    <PMID>12107227</PMID>
  </reference>
  <reference>
    <citation>Contraceptive efficacy of testosterone-induced azoospermia in normal men. World Health Organization Task Force on methods for the regulation of male fertility. Lancet. 1990 Oct 20;336(8721):955-9.</citation>
    <PMID>1977002</PMID>
  </reference>
  <results_reference>
    <citation>Page ST, Amory JK, Anawalt BD, Irwig MS, Brockenbrough AT, Matsumoto AM, Bremner WJ. Testosterone gel combined with depomedroxyprogesterone acetate is an effective male hormonal contraceptive regimen and is not enhanced by the addition of a GnRH antagonist. J Clin Endocrinol Metab. 2006 Nov;91(11):4374-80. Epub 2006 Aug 29.</citation>
    <PMID>16940442</PMID>
  </results_reference>
  <results_reference>
    <citation>Amory JK, Page ST, Anawalt BD, Matsumoto AM, Bremner WJ. Acceptability of a combination testosterone gel and depomedroxyprogesterone acetate male contraceptive regimen. Contraception. 2007 Mar;75(3):218-23. Epub 2007 Jan 16.</citation>
    <PMID>17303493</PMID>
  </results_reference>
  <results_reference>
    <citation>Page ST, Kalhorn TF, Bremner WJ, Anawalt BD, Matsumoto AM, Amory JK. Intratesticular androgens and spermatogenesis during severe gonadotropin suppression induced by male hormonal contraceptive treatment. J Androl. 2007 Sep-Oct;28(5):734-41. Epub 2007 May 9.</citation>
    <PMID>17494097</PMID>
  </results_reference>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <last_update_submitted>September 18, 2008</last_update_submitted>
  <last_update_submitted_qc>September 18, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2008</last_update_posted>
  <responsible_party>
    <name_title>William J Bremner, MD, PhD</name_title>
    <organization>University of Washington</organization>
  </responsible_party>
  <keyword>Male contraception</keyword>
  <keyword>testosterone</keyword>
  <keyword>acyline</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Medroxyprogesterone Acetate</mesh_term>
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Medroxyprogesterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

